Xcout Intel
MycoRx LLC
MycoRx LLC develops new antifungal drug candidates designed to overcome drug resistance and treat fungal infections ranging from recurrent skin conditions to life-threatening sepsis. The company also supports clinical trials for other drug developers and maintains safety standards in the testing and manufacturing of pharmaceutical products.
Subscribe to see MycoRx LLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
MycoRx LLC at a glance
MycoRx LLC is a biotechnology company headquartered in United States. Its most recent funding round raised $600,000 in April 2026. Xcout tracks 1 named person at MycoRx LLC, including Abhiram Maddi (Executive Officer).
MycoRx LLC leadership
- Abhiram MaddiExecutive Officer
MycoRx LLC funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $600,000 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
MycoRx LLC competitors
A few of MycoRx LLC's closest competitors — see the full list of competitors and alternatives →
Pikralida is a biotechnology and contract research organization located in Poland that combines research, development, and innovative formulation services to advance breakthrough therapeutics.
Remedy Plan, Inc. is a Maryland-based biotechnology holding company founded in 2011 that focuses on drug pipelines, patents, and clinical trials.
SFJ Pharmaceuticals is a privately held pharmaceutical development and investment company that helps advance drug candidates through clinical development and regulatory approval. It serves biotechnology and pharmaceutical partners by providing development funding, operational expertise, and global clinical-trial support.
Amplyx Pharmaceuticals, Inc. was a San Diego-based clinical-stage biotechnology company developing treatments for serious and potentially life-threatening fungal infections. Its lead investigational drug, fosmanogepix, was acquired by Pfizer when Pfizer acquired Amplyx in 2021 and is being developed for patients with invasive fungal diseases.
Alopexx, Inc. is a U.S. biotechnology company developing broad-spectrum anti-infective vaccines and antibody-based therapies. Its programs target PNAG, a surface polysaccharide found on many bacterial and fungal pathogens, for potential treatment or prevention of serious infections.
AMR Bio is a clinical-stage biotechnology company headquartered in London, United Kingdom, focused on infection prevention and antimicrobial resistance. The company is dedicated to developing novel anti-infectives, including its Phase 3-ready, first-in-class topical antimicrobial candidate XF-73.
Get MycoRx LLC's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on MycoRx LLC in Xcout Intel
- 1 named person with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access